Exploring the Impact of Semaglutide on Cognitive Function and Anxiety-Related Behaviors in a Murine Model of Alzheimer’s Disease DOI Creative Commons
Ianis Kevyn Stefan Boboc,

Petrica-Daniel Dumitrelea,

Andreea-Daniela Meca

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2689 - 2689

Published: Nov. 25, 2024

Alzheimer's disease (AD), the most prevalent form of dementia, is characterized by progressive cognitive decline and behavioral disturbances, with an increasing incidence as global population ages. This study investigates effects semaglutide (SEM), a glucagon-like peptide-1 analog, on function anxiety-like behavior in transgenic murine model AD. 20 mice were randomly distributed into following groups ( Post-treatment, SEM significantly reduced blood glucose levels AD mice, aligning them those wild-type controls. Cognitive assessments indicated improvement investigation index for SEM-treated compared to receiving vehicle, suggesting benefits. Although did not enhance motor exploratory activities, it displayed potential anxiolytic effect, particularly evident combined anxiety index, notable differences observed before after treatment group. The findings this pilot suggest that may play dual role managing improving glycemic control potentially enhancing function. As landscape evolves, comprehensive approach utilizing could pave way innovative interventions targeting complex interplay metabolic dysfunctions challenging neurodegenerative disorder.

Language: Английский

Alzheimer’s Disease as Type 3 Diabetes: Understanding the Link and Implications DOI Open Access
Mateusz Kciuk, Weronika Kruczkowska, Julia Gałęziewska

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(22), P. 11955 - 11955

Published: Nov. 7, 2024

Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) are two prevalent conditions that present considerable public health issue in aging populations worldwide. Recent research has proposed a novel conceptualization of AD as "type 3 diabetes", highlighting the critical roles insulin resistance impaired glucose metabolism pathogenesis disease. This article examines implications this association, exploring potential new avenues for treatment preventive strategies AD. Key evidence linking to emphasizes metabolic processes contribute neurodegeneration, including inflammation, oxidative stress, alterations signaling pathways. By framing within context, we can enhance our understanding its etiology, which turn may influence early diagnosis, plans, measures. Understanding manifestation opens up possibility employing therapeutic incorporate lifestyle modifications use antidiabetic medications mitigate cognitive decline. integrated approach improve patient outcomes deepen comprehension intricate relationship between neurodegenerative diseases disorders.

Language: Английский

Citations

13
Beyond weight loss: exploring the neurological ramifications of altered gut microbiota post-bariatric surgery DOI Creative Commons

Rashed T. Almheiri,

Baraa Hajjar,

Saif M. I. Alkhaaldi

et al.

Journal of Translational Medicine, Journal Year: 2025, Volume and Issue: 23(1)

Published: Feb. 24, 2025

Language: Английский

Citations

0
Semaglutide improves cognitive function and neuroinflammation in APP/PS1 transgenic mice by activating AMPK and inhibiting TLR4/NF-κB pathway DOI Creative Commons
Yanyu Zhai, Kaili Lu, Yuan Yuan

et al.

Journal of Alzheimer s Disease, Journal Year: 2025, Volume and Issue: unknown

Published: March 28, 2025

Background Alzheimer's disease (AD) causes cognitive function disorder and has become the preeminent cause of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists, semaglutide, have shown positive effects on promoting function. However, research about mechanism semaglutide as a therapeutic intervention in AD is sparse. Objective This study was to investigate efficacy transgenic mouse model pathology explored detailed by modulated neuroinflammatory processes. Methods Male amyloid precursor protein/presenilin 1 (APP/PS1) mice were treated with or vehicle for 8 weeks. Morris water maze test used assess recognition Pathology analysis performed detect deposition plaques. High-throughput sequencing applied specify mechanism. Microglia astrocyte activation assessed immunofluorescent staining. Inflammation cytokine levels evaluated enzyme-linked immunosorbent assay (ELISA). Related proteins pathway western blot. Results Semaglutide treatment attenuated Aβ accumulation enhanced APP/PS1 mice. Through transcriptomic profiling, immunohistochemical staining, ELISA, substantiated inhibit overactivation microglia astrocytes, well curtail secretion inflammatory mediators. Furthermore, robustly activated AMP-activated protein kinase (AMPK) suppressed toll-like 4 (TLR4)/nuclear factor-kappa B (NF-κB) signaling cascade, thus reducing dampening cascade. Conclusions The results demonstrated that mitigated neuroinflammation decelerated advance

Language: Английский

Citations

0
Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson’s disease: A systematic review and meta-analysis DOI Open Access
Madhusudan Prasad Singh, Mahesh Kumar Balasundaram, Alok Singh

et al.

Journal of Neurosciences in Rural Practice, Journal Year: 2025, Volume and Issue: 0, P. 1 - 7

Published: April 25, 2025

Objectives Parkinson’s disease (PD) is a progressive neurodegenerative disorder causing motor as well non-motor symptoms due to dopaminergic neuron degeneration. Type 2 diabetes mellitus (T2DM) linked an increased risk of PD, and glucagon-like peptide-1 (GLP-1) receptor agonists, used in T2DM management, may offer neuroprotective effects. This meta-analysis evaluates the efficacy safety GLP-1 agonists PD. The aim study systematically evaluate agonists’ managing focusing on symptoms, progression, safety. Materials Methods We conducted systematic review following Preferred Reporting Items for Systematic Reviews Meta-Analyses guidelines, searching Cochrane CENTRAL, Medline, Embase, ClinicalTrials.gov up June 2024. Randomized controlled trials (RCTs) comparing (exenatide, liraglutide, lixisenatide) with placebo or standard care were included. Outcomes assessed Movement Disorder Society-Unified Disease Rating Scale (MDS-UPDRS) III, II, IV, Questionnaire (PDQ)-39, adverse events (AEs), serious (SAEs), weight loss. Data analyzed using Review Manager 5.4, bias risk-of-bias tool 2. Results Five RCTs 570 PD patients showed better improvement MDS-UPDRS III (mean difference [MD] = −2.00; 95% confidence interval [CI] −4.23–0.23; P 0.08). No significant differences observed II (MD −1.65; CI −3.39–0.10; 0.06), IV −0.24; −0.91–0.43; 0.48), PDQ-39 −1.68; −4.55–1.18; 0.25). associated loss (risk ratios 2.49; 1.20–5.16; 0.01). found other AEs SAEs. Evidence quality was low very low. Conclusions improve cause Further research needed confirm their

Language: Английский

Citations

0
Short-term effects of Liraglutide and Semaglutide on Weight Gain and Adiposity by Rats Fed a Western Diet DOI

Charlotte Airosus,

Negar Ghasam Ardabili,

Alexia Hyde

et al.

Physiology & Behavior, Journal Year: 2025, Volume and Issue: unknown, P. 114955 - 114955

Published: May 1, 2025

Language: Английский

Citations

0
Exploring the Impact of Semaglutide on Cognitive Function and Anxiety-Related Behaviors in a Murine Model of Alzheimer’s Disease DOI Creative Commons
Ianis Kevyn Stefan Boboc,

Petrica-Daniel Dumitrelea,

Andreea-Daniela Meca

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2689 - 2689

Published: Nov. 25, 2024

Alzheimer's disease (AD), the most prevalent form of dementia, is characterized by progressive cognitive decline and behavioral disturbances, with an increasing incidence as global population ages. This study investigates effects semaglutide (SEM), a glucagon-like peptide-1 analog, on function anxiety-like behavior in transgenic murine model AD. 20 mice were randomly distributed into following groups ( Post-treatment, SEM significantly reduced blood glucose levels AD mice, aligning them those wild-type controls. Cognitive assessments indicated improvement investigation index for SEM-treated compared to receiving vehicle, suggesting benefits. Although did not enhance motor exploratory activities, it displayed potential anxiolytic effect, particularly evident combined anxiety index, notable differences observed before after treatment group. The findings this pilot suggest that may play dual role managing improving glycemic control potentially enhancing function. As landscape evolves, comprehensive approach utilizing could pave way innovative interventions targeting complex interplay metabolic dysfunctions challenging neurodegenerative disorder.

Language: Английский

Citations

0